Skip to content
Home▶ Journals▶ Academia Journal of Medicine▶Archive▶Vol. 2 No. 2 (2019)▶To Study the Occurrence of Non-Alcoholic Fatty Liver…
Academia Journal of Medicine
Print ISSN 2663-8282 · Online ISSN 2663-8290
Original Article

To Study the Occurrence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus.

, ,
Siddharth Arya — Post Graduate Student, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre
Jigar M Haria — Professor, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre
Amit Mishra — Assistant Professor, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre.
Published 30 Jan 2020 Vol. 2 No. 2 (2019), pp. 207-210
Formats:PDF 🔒 Subscription
🔒 PDF

Abstract

Background: Macrovascular and Microvascular complications are well evaluated in DM but NAFLD is the most neglected and unevaluated  complication among DM.Fibroscan is the non-invasive method for assessing liver fibrosis which has high reproducibility and  accuracySubjects and Methods: It was a Case Control study. Fibrosis was assessed by fibroscan and was then quantified. Results: In our  study there was a significant difference seen among the different grades of fibrosis among controls and cases (p=0.004). The mean fibrosis  score too was high among cases (13.498) as compared to controls (6.052). The overall prevalence of NAFLD (F2-F4) was found to be 50%  among cases as compared to 14% in controls.Conclusion: Diabetes has a significant etiological role in occurrence of NAFLD in population.  Fibroscan has a substantial role in screening and diagnosing diabetics for NAFLD and fibrosis, thus advocating its use is recommended to  prevent understudied and unrecognized complication of DM preventing mortality and morbidity. 

KeywordsNAFLDDiabetesFibroscanLSMFibrosis
🔒 Full text available to subscribers
  • PDF — print-ready version
  1. 1. Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman RK, et al. Nonalcoholic fatty liver in a developing country is responsible for
  2. significant liver disease. Hepatology. 2010 Dec;52(6):2248–9. 2. Sasso M, Beaugrand M, deLedinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36:1825–35.
  3. 3. American Diabetes Association. Standards of medical care in diabetes-- 2014. Diabetes Care. 2014 Jan;37Suppl 1: S14-80.
  4. 4. Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan HL-Y, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010 Feb;51(2):454–62.
  5. 5. Agarwal AK, Jain V, Singla S, Baruah BP, Arya V, Yadav R, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India. 2011 Jun; 59:351–4.
  6. 6. Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, et al. Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. Hepatol Res. 2013 Jul;43(7):735–42.

Looking up citing articles…